Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Calgary
$27,000.00
CD276 (B7-H3) Tumor-Associated Antigen mRNA Vaccine for Glioblastoma
FY 2025-26
Summary
Glioblastoma (GBM) is the most common and aggressive brain cancer. Most patients survive only about a year after diagnosis. Many immunotherapies that have been effective in other cancers have had limited success in GBM. This is due to GBM tumors being highly diverse, suppressing the immune system, and challenging for immune cells to penetrate. Vaccines that teach the immune system to recognize tumor markers have shown promise, but current approaches are difficult to manufacture or do not create strong enough immune responses. Recent success with mRNA vaccines, including those used during the COVID-19 pandemic, has shown that mRNA packaged in lipid nanoparticles (LNPs) can safely stimulate strong, targeted immune activation. We believe that this technology could be leveraged to help the immune system better recognize GBM tumors. Our goal is to test whether an mRNA-LNP vaccine targeting CD276, a molecule found on GBM cells (but rarely on healthy tissue), can prime the immune system to attack the tumor. Work in our lab has already shown that our LNP platform can activate robust T-cell responses against a known GBM mutation. This suggests that similar responses may be achieved for more common tumor markers such as CD276. We will test this idea in three steps. First, we will determine whether the CD276 mRNA-LNP vaccine can elicit CD4 and CD8 T-cell responses in mice. Next, we will study changes in the tumor environment following vaccination, such as which immune cells are activated and if they are stimulatory or immunpsuppressing. Finally, we will measure whether the vaccine is safe and if it can improve survival in mouse models of GBM. If successful, this work may point to a novel, scalable, and more accessible vaccine strategy to treat GBM and potentially other cancers.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
573058
Name
Peng Jocelyn
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
CD276 (B7-H3) Tumor-Associated Antigen mRNA Vaccine for Glioblastoma
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cd276 (B7-H3); Cellular Response; Gbm Heterogeneity; Glioblastoma Multiforme (Gbm); Immunotherapy; Lipid Nanoparticle (Lnp); Mrna Vaccine; Tolerance; Tumor Microenvironment; Tumor-Associated Antigens (Taas)
Abstract
Glioblastoma (GBM) is the most common and aggressive brain cancer. Most patients survive only about a year after diagnosis. Many immunotherapies that have been effective in other cancers have had limited success in GBM. This is due to GBM tumors being highly diverse, suppressing the immune system, and challenging for immune cells to penetrate. Vaccines that teach the immune system to recognize tumor markers have shown promise, but current approaches are difficult to manufacture or do not create strong enough immune responses. Recent success with mRNA vaccines, including those used during the COVID-19 pandemic, has shown that mRNA packaged in lipid nanoparticles (LNPs) can safely stimulate strong, targeted immune activation. We believe that this technology could be leveraged to help the immune system better recognize GBM tumors. Our goal is to test whether an mRNA-LNP vaccine targeting CD276, a molecule found on GBM cells (but rarely on healthy tissue), can prime the immune system to attack the tumor. Work in our lab has already shown that our LNP platform can activate robust T-cell responses against a known GBM mutation. This suggests that similar responses may be achieved for more common tumor markers such as CD276. We will test this idea in three steps. First, we will determine whether the CD276 mRNA-LNP vaccine can elicit CD4 and CD8 T-cell responses in mice. Next, we will study changes in the tumor environment following vaccination, such as which immune cells are activated and if they are stimulatory or immunpsuppressing. Finally, we will measure whether the vaccine is safe and if it can improve survival in mouse models of GBM. If successful, this work may point to a novel, scalable, and more accessible vaccine strategy to treat GBM and potentially other cancers.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Peng, Jocelyn
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~